{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:47Z","timestamp":1786980107772,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u251c\u2562ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the diagnostic accuracy of a commercially available test kit for noninvasive prenatal determination of the fetal RhD status (NIPT-RhD) with a focus on early gestation and multiple pregnancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The FetoGnost RhD assay (Ingenetix, Vienna, Austria) is routinely applied for clinical decision making either in woman with anti-D alloimmunization or to target the application of routine antenatal anti-D prophylaxis (RAADP) to women with a RhD positive fetus. Based on existing data in the laboratory information system the newborn\u2019s serological RhD status was compared with NIPT RhD results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since 2009 NIPT RhD was performed in 2968 pregnant women between weeks 5\u2009+\u20096 and 40\u2009+\u20090 of gestation (median 12\u2009+\u20096) and conclusive results were obtained in 2888 (97.30%) cases. Diagnostic accuracy was calculated from those 2244 (77.70%) cases with the newborn\u2019s serological RhD status reported. The sensitivity of the FetoGnost RhD assay was 99.93% (95% CI 99.61\u201399.99%) and the specificity was 99.61% (95% CI 98.86\u201399.87%). No false-positive or false-negative NIPT RhD result was observed in 203 multiple pregnancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NIPT RhD results are reliable when obtained with FetoGnost RhD assay. Targeted routine anti-D-prophylaxis can start as early as 11\u2009+\u20090\u00a0weeks of gestation in singleton and multiple pregnancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-021-06055-1","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T01:02:58Z","timestamp":1617930178000},"page":"1191-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status"],"prefix":"10.1007","volume":"304","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-5397","authenticated-orcid":false,"given":"Tobias J.","family":"Legler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"L\u00fchrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Korschineck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"6055_CR1","doi-asserted-by":"publisher","first-page":"102947","DOI":"10.1016\/j.transci.2020.102947","volume":"59","author":"CA Hyland","year":"2020","unstructured":"Hyland CA, O\u2019Brien H, Flower RL, Gardener GJ (2020) Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation. Transfus Apher Sci 59:102947","journal-title":"Transfus Apher Sci"},{"key":"6055_CR2","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/j.1537-2995.2007.01437.x","volume":"47","author":"K Finning","year":"2007","unstructured":"Finning K, Martin P, Summers J, Daniels G (2007) Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 47:2126\u20132133","journal-title":"Transfusion"},{"key":"6055_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1471-0528.2010.02518.x","volume":"117","author":"K Gutensohn","year":"2010","unstructured":"Gutensohn K, M\u00fcller SP, Thomann K, Stein W, Suren A, K\u00f6rtge-Jung S, Schl\u00fcter G, Legler TJ (2010) Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. BJOG 117:722\u2013729","journal-title":"BJOG"},{"key":"6055_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/j.1471-0528.2011.03028.x","volume":"118","author":"P Scheffer","year":"2011","unstructured":"Scheffer P, van der Schoot C, Page-Christiaens G, de Haas M (2011) Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 118:1340\u20131348","journal-title":"BJOG"},{"key":"6055_CR5","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1111\/bjh.16500","volume":"189","author":"H O\u2019Brien","year":"2020","unstructured":"O\u2019Brien H, Hyland C, Schoeman E, Flower R, Daly J, Gardener G (2020) Non-invasive prenatal testing (NIPT) for fetal Kell, Duffy and Rh blood group antigen prediction in alloimmunised pregnant women: power of droplet digital PCR. Br J Haematol 189:e90\u2013e94","journal-title":"Br J Haematol"},{"key":"6055_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/trf.15116","volume":"59","author":"A Orzi\u0144ska","year":"2019","unstructured":"Orzi\u0144ska A, Guz K, Mikula M, Kluska A, Balabas A, Ostrowski J, Uhrynowska M, Kope\u0107 I, D\u0119bska M, Luterek K, Brojer E (2019) Prediction of fetal blood group and platelet antigens from maternal plasma using next-generation sequencing. Transfusion 59:1102\u20131107","journal-title":"Transfusion"},{"key":"6055_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000505161","volume":"47","author":"S Wienzek-Lischka","year":"2020","unstructured":"Wienzek-Lischka S, Bachmann S, Froehner V, Bein G (2020) Potential of next generation sequencing in noninvasive fetal molecular blood group genotyping. Transfus Med Hemother 47:14\u201322","journal-title":"Transfus Med Hemother"},{"key":"6055_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/tme.12091","volume":"24","author":"H Qureshi","year":"2014","unstructured":"Qureshi H, Massey E, Kirwan D, Davies T, Robson S, Wjthe J, Jones J, Allard S (2014) BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 24:8\u201320","journal-title":"Transfus Med"},{"key":"6055_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/trf.15635","volume":"60","author":"B Gudlaugsson","year":"2020","unstructured":"Gudlaugsson B, Hjartardottir H, Svansdottir G, Gudmundsdottir G, Kjartansson S, Jonsson T, Gudmundsson S, Halldorsdottir AM (2020) Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis. Transfusion 60:175\u2013183","journal-title":"Transfusion"},{"key":"6055_CR10","doi-asserted-by":"publisher","first-page":"102950","DOI":"10.1016\/j.transci.2020.102950","volume":"59","author":"TJ Legler","year":"2020","unstructured":"Legler TJ (2020) RhIg for the prevention Rh immunization and IVIg for the treatment of affected neonates. Transfus Apher Sci 59:102950","journal-title":"Transfus Apher Sci"},{"key":"6055_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJM199812103392402","volume":"339","author":"YM Lo","year":"1998","unstructured":"Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, Poon PM, Redman CW, Wainscoat JS (1998) Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 339:1734\u20131738","journal-title":"N Engl J Med"},{"key":"6055_CR12","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(05)60534-X","volume":"352","author":"BH Faas","year":"1998","unstructured":"Faas BH, Beuling EA, Christiaens GC, von dem Borne AE, van der Schoot CE (1998) Detection of fetal RhD-specific sequences in maternal plasma. Lancet 352:1196","journal-title":"Lancet"},{"key":"6055_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1537-2995.2011.03362.x","volume":"52","author":"FB Clausen","year":"2012","unstructured":"Clausen FB, Christiansen M, Steffensen R et al (2012) Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 52:752\u2013758","journal-title":"Transfusion"},{"key":"6055_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/pd.4419","volume":"34","author":"FB Clausen","year":"2014","unstructured":"Clausen FB, Steffensen R, Christiansen M, Rudby M, Jakobsen MA, Jakobsen TR, Krog GR, Madsen RD, Nielsen KR, Rieneck K, Sprog\u00f8e U, Homburg KM, Baech J, Dziegiel MH, Grunnet N (2014) Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. Prenat Diagn 34:1000\u20131005","journal-title":"Prenat Diagn"},{"key":"6055_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/MOH.0000000000000379","volume":"24","author":"CE van der Schoot","year":"2017","unstructured":"van der Schoot CE, de Haas M, Clausen FB (2017) Genotyping to prevent Rh disease: has the time come? Curr Opin Hematol 24:544\u2013550","journal-title":"Curr Opin Hematol"},{"key":"6055_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3310\/hta22130","volume":"22","author":"P Saramago","year":"2018","unstructured":"Saramago P, Yang H, Llewellyn A, Walker R, Harden M, Palmer S et al (2018) High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technol Assess 22:13","journal-title":"Health Technol Assess"},{"key":"6055_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/14767058.2014.882306","volume":"27","author":"YJ Zhu","year":"2014","unstructured":"Zhu YJ, Zheng YR, Li L et al (2014) Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis. J Matern Fetal Neonatal Med 27:1839\u20131844","journal-title":"J Matern Fetal Neonatal Med"},{"key":"6055_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12916-019-1254-4","volume":"17","author":"H Yang","year":"2019","unstructured":"Yang H, Llewellyn A, Walker R et al (2019) High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis. BMC Med 17:37","journal-title":"BMC Med"},{"key":"6055_CR19","doi-asserted-by":"crossref","unstructured":"van der Schoot CE, Winkelhorst D, Clausen FB (2018) Non-invasive fetal blood group typing. Noninvasive prenatal testing (NIPT). Applied genomics in prenatal screening and prenatal diagnosis. Page-Christiaens L, Klein H-G (Eds.).","DOI":"10.1016\/B978-0-12-814189-2.00008-6"},{"key":"6055_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12884-020-2742-4","volume":"20","author":"B Runkel","year":"2020","unstructured":"Runkel B, Bein G, Sieben W, Sow D, Polus S, Fleer D (2020) Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review. BMC Pregnancy Childbirth 20:83. https:\/\/doi.org\/10.1186\/s12884-020-2742-4","journal-title":"BMC Pregnancy Childbirth"},{"key":"6055_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/voxs.12521","volume":"15","author":"FB Clausen","year":"2020","unstructured":"Clausen FB (2020) Cell-free fetal DNA and fetal blood group genotyping: non-invasive prenatal testing. ISBT Sci Ser 15:46\u201351","journal-title":"ISBT Sci Ser"},{"key":"6055_CR22","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/j.1537-2995.2006.01044.x","volume":"46","author":"MG Grootkerk-Tax","year":"2006","unstructured":"Grootkerk-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE (2006) Evaluation of prenatal RhD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 46:2142\u20132148","journal-title":"Transfusion"},{"key":"6055_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/pd.1783","volume":"27","author":"TJ Legler","year":"2007","unstructured":"Legler TJ, Liu Z, Mavrou A, Finning K, Hromadnikova I, Galbiati S, Meaney C, Hult\u00e9n MA, Crea F, Olsson ML, Maddocks DG, Huang D, Armstrong Fisher S, Sprenger-Haussels M, Ait Soussan A, van der Schoot CE (2007) Workshop report on the extraction of fetal DNA from maternal plasma. Prenat Diagn 27:824\u2013829","journal-title":"Prenat Diagn"},{"key":"6055_CR24","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1373\/clinchem.2006.074997","volume":"52","author":"KC Chan","year":"2006","unstructured":"Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, Lau TK, Chim SS, Chung GT, Nicolaides KH, Lo YM (2006) Hypermethylated Rassf1a in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 52:2211\u20132218","journal-title":"Clin Chem"},{"key":"6055_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/pd.2770","volume":"31","author":"AT Bombard","year":"2011","unstructured":"Bombard AT, Akolekar R, Farkas DH et al (2011) Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 31:802\u2013808","journal-title":"Prenat Diagn"},{"key":"6055_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/AOG.0000000000001741","volume":"128","author":"KJ Moise Jr","year":"2016","unstructured":"Moise KJ Jr, Gandhi M, Boring NH et al (2016) Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy. Obstet Gynecol 128:1340\u20131346. https:\/\/doi.org\/10.1097\/AOG.0000000000001741","journal-title":"Obstet Gynecol"},{"key":"6055_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.tracli.2008.01.003","volume":"14","author":"C Rouillac-Le Sciellour","year":"2007","unstructured":"Rouillac-Le Sciellour C, Serazin V, Brossard Y, Oudin O, Le Van KC, Colin Y, Guidicelli Y, Menu M, Cartron JP (2007) Noninvasive fetal RhD genotyping from maternal plasma. Use of a new developed free DNA fetal kit RhD. Transfus Clin Biol 14:572\u2013577","journal-title":"Transfus Clin Biol"},{"key":"6055_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/tme.12605","volume":"29","author":"D Londero","year":"2019","unstructured":"Londero D, Stampalija T, Bolzicco D et al (2019) Fetal RHD detection from circulating cell-free fetal DNA in maternal plasma: validation of a diagnostic kit using automatic extraction and frozen DNA. Transfus Med 29:408\u2013414. https:\/\/doi.org\/10.1111\/tme.12605","journal-title":"Transfus Med"},{"key":"6055_CR29","doi-asserted-by":"publisher","first-page":"i5789","DOI":"10.1136\/bmj.i5789","volume":"355","author":"M De Haas","year":"2016","unstructured":"De Haas M, Thurik FF, van der Ploeg CPB et al (2016) Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ 355:i5789","journal-title":"BMJ"},{"key":"6055_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/AOG.0b013e31825d33d9","volume":"120","author":"AT Wikman","year":"2012","unstructured":"Wikman AT, Tiblad E, Karlsson A et al (2012) Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 120:227\u2013234","journal-title":"Obstet Gynecol"},{"key":"6055_CR31","doi-asserted-by":"publisher","first-page":"g5243","DOI":"10.1136\/bmj.g5243","volume":"349","author":"LS Chitty","year":"2014","unstructured":"Chitty LS, Finning K, Wade A et al (2014) Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ 349:g5243","journal-title":"BMJ"},{"key":"6055_CR32","doi-asserted-by":"publisher","first-page":"606.e1","DOI":"10.1016\/j.ajog.2016.06.054","volume":"215","author":"A Vivanti","year":"2016","unstructured":"Vivanti A, Benachi A, Huchet FX et al (2016) Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy. Am J Obstet Gynecol 215:606.e1-606.e5","journal-title":"Am J Obstet Gynecol"},{"key":"6055_CR33","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/aogs.13191","volume":"96","author":"K Haimila","year":"2017","unstructured":"Haimila K, Sulin K, Kuosmanen M et al (2017) Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women\u2014outcome of the first two years of a national program in Finland. Acta Obstet Gynecol Scand 96:1228\u20131233","journal-title":"Acta Obstet Gynecol Scand"},{"key":"6055_CR34","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/j.1537-2995.2008.01843.x","volume":"48","author":"SP M\u00fcller","year":"2008","unstructured":"M\u00fcller SP, Bartels I, Stein W, Emons G, Gutensohn K, K\u00f6hler M, Legler TJ (2008) The determination of the fetal RhD status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 48:2292\u20132301","journal-title":"Transfusion"},{"key":"6055_CR35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1537-2995.2007.01533.x","volume":"48","author":"JM Minon","year":"2008","unstructured":"Minon JM, Gerard C, Senterre JM et al (2008) Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 48:373\u2013381","journal-title":"Transfusion"},{"key":"6055_CR36","first-page":"50","volume":"20","author":"T Legler","year":"2020","unstructured":"Legler T, Bein G, Bugert P, Schwartz D (2020) Validierung von Testverfahren zur Bestimmung des fetalen RHD-Status aus dem Blut D-negativer Frauen in der Schwangerschaft. Transfusionsmedizin 20:50\u201354","journal-title":"Transfusionsmedizin"},{"key":"6055_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5694\/j.1326-5377.2009.tb02668.x","volume":"191","author":"CA Hyland","year":"2009","unstructured":"Hyland CA, Gardener GJ, Davies H et al (2009) Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust 191:21\u201325","journal-title":"Med J Aust"},{"key":"6055_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.yexmp.2010.09.002","volume":"89","author":"L Zejskova","year":"2010","unstructured":"Zejskova L, Jancuskova T, Kotlabova K, Doucha J, Hromadnikova I (2010) Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma\u2013next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol 89:241\u2013247","journal-title":"Exp Mol Pathol"},{"key":"6055_CR39","doi-asserted-by":"publisher","first-page":"e45073","DOI":"10.1371\/journal.pone.0045073","volume":"7","author":"HE White","year":"2012","unstructured":"White HE, Dent CL, Hall VJ, Crolla JA, Chitty LS (2012) Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis. PLoS ONE 7:e45073","journal-title":"PLoS ONE"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-021-06055-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T19:10:13Z","timestamp":1724785813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-021-06055-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6055"],"URL":"https:\/\/doi.org\/10.1007\/s00404-021-06055-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-200690\/v1","asserted-by":"object"}]},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tobias Legler receives consultation fees from LADR GmbH and participates in the revenue of his employer. Irina Korschineck is the owner and manager of the company Ingenetix GmbH. Sandra L\u00fchrig and Dieter Schwartz do not have any conflicts of interest\/competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Ethics Committee of Vienna University (approval no. 1927\/2020), the approval has been published:\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Before blood sample collection for NIPT-RhD, informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable, only anonymized data are reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}